Will PARP inhibitors expand their role beyond BRCA mutations?


According to Branislav Bystricky, Faculty Hospital TN-Fakultna nemocnica Trencin, Slovakia and Associate Editor of the Daily Reporter practice changing results for women with ovarian cancer will be presented at ESMO 2019 Congress, held in Barcelona, Spain, from 27 September to 1 October. Findings will likely respond to a key question in oncology around the potential expanded role of these agents beyond the treatment of BRCA mutation in ovarian cancer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.